Sutro Biopharma, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jane Chung
- Full Time Employees
- 269
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 111 Oyster Point Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Sep 27, 2018
- CIK
- 0001382101
- Website
- sutrobio.com
- Similar Companies
- Business
- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company, develops site-specific and novel-format antibody drug conjugates (ADCs) for cancer using its proprietary cell-free protein synthesis platforms, XpressCF and XpressCF+; core wholly owned product candidates include STRO-004, a tissue factor-targeting ADC for solid tumors such as cervical, lung and breast cancers with U.S. FDA IND clearance received in November 2025 and first-in-human dosing on track before year-end, STRO-006, a highly selective integrin beta-6 ADC for multiple solid tumors advancing toward clinical development in 2026, and a wholly owned dual-payload ADC program combining cytotoxic and immunostimulatory payloads with IND submission targeted for 2027; additional programs encompass STRO-001 targeting CD74 for multiple myeloma and non-Hodgkin lymphoma, STRO-002 (luveltamab tazevibulin) targeting folate receptor-alpha for ovarian and endometrial cancers, and STRO-003 targeting ROR1. Founded in 2003 and headquartered in South San Francisco, California, the company operates primarily in the United States with a global collaboration pipeline including partnerships with Astellas on dual-payload immunostimulatory ADCs where one program entered IND-enabling toxicology in early 2025, Ipsen on STRO-003 which Ipsen opted not to advance in 2025, Merck on cytokine derivatives, and a manufacturing partnership with VGXI for luvelta production; recent developments feature a strategic portfolio review and organizational restructuring announced in March and September 2025 prioritizing ADC programs, cessation of San Carlos manufacturing facility operations by year-end 2025, leadership transition with Jane Chung assuming CEO role from Bill Newell in March 2025 and Greg Chow appointed CFO in June 2025, entry into a research collaboration with the U.S. FDA in July 2025 to advance ADC regulatory standards, and preclinical data presentations at conferences including World ADC and SITC in November 2025 highlighting dual-payload ADCs' potential to overcome resistance.
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
Sutro Biopharma (NASDAQ:STRO) Trading 10.4% Higher on Analyst Upgrade
Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of “Hold” from Analysts
Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026
Sutro Biopharma to Participate in Upcoming Investor Conferences
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock?
Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of “Hold” by Analysts
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Hold” from Brokerages
Sutro Biopharma, Inc. (STRO) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation Transcript
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference